The high fragmentation of nuclear circulating DNA (cirDNA) relies on chromatin organization
and protection or packaging within mononucleosomes, the smallest and the most stabilized …

Precision medicine has transformed the way urothelial carcinoma is managed. However,
current practices are limited by the availability of tissue samples for genomic profiling and …

Cell-free DNA molecules are released into the plasma via apoptotic or necrotic events and
active release mechanisms, which carry the genetic and epigenetic information of its origin …

Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in
both research and clinical settings. ctDNA can be used to identify actionable mutations to …

Background Early detection of hepatocellular carcinoma (HCC) is important in order to
improve patient prognosis and survival rate. Methylation sequencing combined with neural …

Simple Summary Liquid biopsies provide a non-invasive means to diagnose and profile
tumors when tissue is not available. Sequence-based analysis of cell-free DNA (cfDNA) is …

Identifying novel circulating biomarkers predictive of response and informative about the
mechanisms of resistance, is the new challenge for breast cancer (BC) management. The …

Background Recent advances in circulating cell-free DNA (cfDNA) analysis from biofluids
have opened new avenues for liquid biopsy (LB). However, current cfDNA LB assays are …

Background The current methodology used to detect, diagnose, and monitor many types of
cancers requires invasive tissue biopsy testing. Recently, liquid biopsy using blood, plasma …

Early detection of primary bladder cancer (BCa) is vital, because stage and grade have
been generally accepted not only as categorical but also as prognostic factors in patients …